Question · asked by 1 review
Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo: Withdrawals due to adverse events
- Population
- anemia in patients with rheumatoid arthritis
- Intervention
- Erythropoietin (subcutaneous or intravenous at varying dosages)
- Comparison
- placebo
- Outcome
- Withdrawals due to adverse events
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo Withdrawals due to adverse events · anemia in patients with rheumatoid arthritis The review found no eligible studies for this question. Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis (2013) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis 2013 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.